^
Association details:
| Biomarker: | RET positive |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | Retevmo (selpercatinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib
Published date:
07/14/2022
Excerpt:
Among 178 RET-positive cases, 147 (82.6%) harbored a SNV and 31 (17.4%) a RET in-frame indel….Patients harboring an indel were found to have an aggressive disease and 2 of them were treated with selpercatinib, experiencing a good response to the treatment....Two RET indel-positive patients showed a partial response to the treatment with a highly selective RET inhibitor; thus, these RET indels can be considered actionable mutations.
DOI:
10.1210/clinem/dgac325
